Gilead Sciences Q2 FY25: where the revenue came from and where it went
The whole income statement of Gilead Sciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 7, 2025
Revenue$7.08B
+2% year over year
Gross profit$5.58B
79% margin
Operating profit$2.47B
35% margin
Net profit$1.96B
28% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 7.08 | 100% | +2% |
| Biktarvy | 3.53 | 50% | +9% |
| Other revenue | 1.13 | 16% | |
| Descovy | 0.65 | 9% | +35% |
| Yescarta | 0.39 | 6% | −5% |
| Genvoya | 0.38 | 5% | −14% |
| Trodelvy | 0.36 | 5% | +14% |
| Liver disease products | 0.34 | 5% | −28% |
| Odefsey | 0.30 | 4% | −5% |
| Cost of revenue | −1.50 | 21% | |
| Gross profit | 5.58 | 79% margin | +1pp |
| SG&A | −1.37 | 19% | −1pp |
| Other | −1.74 | 25% | +0pp |
| Operating profit | 2.47 | 35% margin | −3pp |
| Interest & other costs | −0.05 | ||
| Tax | −0.47 | ||
| Net profit | 1.96 | 28% margin | +4pp |
347 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest